Medicine Recommendations

Schizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour, severe anxiety

Drug induced extrapyramidal side effects

Asthma

Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2-agonist

COPD

Depressive illness

a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.

Restriction: Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.

Hospital specialist initiation only for long term severe and disabling depressive illness, after trial of standard antidepressant treatment and as an adjunct to other antidepressant medication

Except for mitochondrial disorders

Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed.

MHRA Aug 2018 Update - Ulipristal

Drug Safety Update March 2020 - Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury

COPD

COPD

NICE TA665 - Upadacitinib for treating severe rheumatoid arthritis

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA768)

NICE TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

NICE TA744 - Upadacitinib for treating moderate rheumatoid arthritis

Ustekinumab for treating moderately to severely active ulcerative colitis (TA 633)

Ulcerative Colitis

Treatment of active psoriatic arthritis - rapid review of TA 313 (NICE TA340)

NICE TA 340 - Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) 

MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis

Moderate to severe plaque psoriasis (NICE TA180)

NICE TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis

MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis

Moderately to severely active Crohn’s disease after previous treatment (NICE TA456)

NICE TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment